Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425247.2023.2209314 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging systemic treatments for asthma and allergic diseases: New tricks, same dog?
J Allergy Clin Immunol Pract
September 2025
Associate Professor of Medicine, Medical Director of Clinical Asthma Research, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center. Electronic address:
Asthma and allergic diseases are heterogeneous conditions driven by complex immunological pathways, with type 2 (T2) inflammation being a key but not exclusive component. Advances in immunology have spurred interest in a breadth of mechanisms and innovative therapeutic strategies, including novel targets, extended dosing intervals, and combined-target therapies. This clinical commentary provides a critical overview of ongoing clinical trials and emerging evidence supporting the use of these therapies in asthma and other allergic conditions.
View Article and Find Full Text PDFA Multicenter, Open-Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial.
Pharmacotherapy
September 2025
Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan Health System, Ann Arbor, Michigan, USA.
Introduction: Pediatric plastic bronchitis (PB) is a rare complication of surgically palliated congenital heart disease (CHD). Fibrin casts obstruct airways and can cause respiratory distress. There are no therapeutics approved by the United States Food and Drug Administration to treat PB, but inhaled tissue plasminogen activator (tPA) has been anecdotally used to relieve symptoms.
View Article and Find Full Text PDFIn silico identification of peptidomimetic inhibitors targeting PXR and RXR interaction to overcome the inactivation of vitamin D in asthma.
Mol Divers
September 2025
Medical Biotechnology Laboratory (MedBiotech), Faculty of Medecine and Pharmacy of Rabat, Mohammed Vth University in Rabat, Rabat, Morocco.
Asthma is a chronic inflammatory disorder of the airways. Standard treatments, such as inhaled corticosteroids like fluticasone, beclomethasone, and budesonide, are effective in managing asthma symptoms by reducing inflammation through immune suppression. However, prolonged corticosteroid therapy can impair vitamin D metabolism, exacerbating vitamin D deficiency, which is essential for immune regulation and anti-inflammatory responses via the vitamin D receptor (VDR).
View Article and Find Full Text PDFInhaled Cannabis, Asthma, and Chronic Obstructive Pulmonary Disease: A Population-Based Cross-Sectional Study of n = 379,049.
J Gen Intern Med
September 2025
Center for Data to Discovery and Delivery Innovation (3DI), San Francisco VA Health Care System, San Francisco, CA, USA.
Background: Cannabis may cause chronic pulmonary disease. Prior studies have been limited by low cannabis exposure, lack of data on tobacco cigarettes, and/or limited numbers of those without tobacco cigarette use.
Objective: To examine whether inhaled cannabis associated with asthma and chronic obstructive pulmonary disease, independent of tobacco cigarettes.
Greenhouse Gas Emissions Related to Inhalers.
JAMA
September 2025
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.